EBIT Margin: Earnings before interest and taxes as a portion of total revenues. Calculated as: EBIT / Total Revenues
Monte Rosa Therapeutics, Inc. (GLUE) had EBIT Margin of -258.26% for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$12.77M |
|
$-27.08M |
|
-- |
|
$12.77M |
|
$45.74M |
|
$-32.98M |
|
$2.72M |
|
$-30.26M |
|
$-30.26M |
|
$-27.08M |
|
$-27.08M |
|
$-27.08M |
|
$-27.08M |
|
$-32.98M |
|
$-30.88M |
|
82.40M |
|
82.40M |
|
$-0.33 |
|
$-0.33 |
|
| Balance Sheet Financials | |
$401.82M |
|
$27.60M |
|
$58.02M |
|
$459.84M |
|
$61.44M |
|
-- |
|
$152.56M |
|
$214.00M |
|
$245.84M |
|
$245.84M |
|
$245.84M |
|
61.79M |
|
| Cash Flow Statement Financials | |
$20.22M |
|
$-36.77M |
|
$0.73M |
|
$229.12M |
|
$213.29M |
|
$-15.82M |
|
$14.56M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.54 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-258.26% |
|
|
EBIT Margin |
-258.26% |
-- |
|
-236.98% |
|
-212.10% |
|
$16.28M |
|
-- |
|
-- |
|
-- |
|
0.03 |
|
-- |
|
2.57 |
|
35.00 |
|
-11.02% |
|
-11.02% |
|
-5.89% |
|
-11.02% |
|
$3.98 |
|
$0.20 |
|
$0.25 |
|